Kailera Therapeutics (KLRA) investor relations material

Company overview and business model

• Advanced clinical-stage biotechnology company focused on obesity care, developing a diversified pipeline of GLP-1-based therapeutics targeting significant unmet needs in obesity management.

• Lead product candidate, ribupatide, is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 trials, with additional oral and injectable candidates in development.

• Holds exclusive worldwide rights (excluding Greater China) to all product candidates through a strategic collaboration with Hengrui.

• Strategy includes advancing lead and oral candidates, leveraging Hengrui’s data, and building scalable manufacturing and commercial capabilities.

Financial performance and metrics

• No revenue generated to date; net losses of $219.7 million (2024) and $149.0 million (2025); accumulated deficit of $368.7 million as of December 31, 2025.

• Operating expenses were $230.4 million (2024) and $158.3 million (2025), with R&D expenses increasing to $109.1 million in 2025.

• Cash, cash equivalents, and marketable securities totaled $652.7 million as of December 31, 2025.

• Raised $900 million from leading life science investors prior to IPO.

Use of proceeds and capital allocation

• Estimated net proceeds of $458.7 million (or $528.5 million if underwriters’ option exercised) based on a $15.00/share IPO price.

• Proceeds allocated to fund development of ribupatide (approx. $625 million), oral ribupatide ($150 million), KAI-7535 ($50 million), other R&D (including KAI-4729), and general corporate purposes.

• Funds expected to support operations into Q2 2028; additional capital will be required to complete development and commercialization.